Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec

Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec: a Retrospective Study

Retrospective multicenter study analyzing data gathered from medical records and diabetes management platforms to assess the effect of using Insulin Degludec (Tresiba®) on measures of diabetes control.

People with type 1 diabetes who switched to Insulin Degludec from another basal insulin between 1/5/2019 and 1/6/2021 will be included.

Glycemic control from 12 months before the switch to Insulin Degludec will be compared to glycemic control of the 12 months after the switch.

Inclusion Criteria:

• People with T1D ≥18 years at the moment of switch to Insulin Degludec
• Diagnosed with T1D ≥2 years before switch to Insulin Degludec
• On basal-bolus insulin therapy with insulin pens ≥2 years before switch to Insulin Degludec
• ≥6 months use of Insulin Degludec at moment of datacollection
• Using continuous glucose monitoring ≥2 years before switch to Insulin Degludec

Exclusion Criteria:

• People with T1D <18 years at the moment of switch to Insulin Degludec
• People without T1D or with T1D <2 years before switch to Insulin Degludec
• Women with T1D who are pregnant or planning pregnancy during -12 and +12 months
• Not using basal-bolus insulin therapy with insulin pens during -24 and +6 months
• Start to use non-insulin antidiabetic agents between -12 and +12 months
• Having received treatment with oral or injectable corticosteroids during -12 and +12 months
• Undergoing hemodialysis, renal transplantation, or beta cell transplantation during -12 and +12 months
• <6 months use of Insulin Degludec at moment of datacollection
• Not using continuous glucose monitoring or <2 years before switch to Insulin Degludec